The holistic 3M modality of drug delivery nanosystems for cancer therapy.
暂无分享,去创建一个
Yongjun Wang | Cong Luo | Jin Sun | Zhonggui He | Jin Sun | Yongjun Wang | Zhonggui He | C. Luo
[1] Lei Han,et al. Construction of Novel Brain-Targeting Gene Delivery System by Natural Magnetic Nanoparticles , 2011 .
[2] Xin Gao,et al. Dual docetaxel/superparamagnetic iron oxide loaded nanoparticles for both targeting magnetic resonance imaging and cancer therapy. , 2011, Biomaterials.
[3] Resham Bhattacharya,et al. Efficient Delivery of Gold Nanoparticles by Dual Receptor Targeting , 2011, Advanced materials.
[4] Neil Desai,et al. Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and nab-Paclitaxel , 2008, Clinical Cancer Research.
[5] É. Duguet,et al. The formation of supported lipid bilayers on silica nanoparticles revealed by cryoelectron microscopy. , 2005, Nano letters.
[6] H. Maeda,et al. Exploiting the enhanced permeability and retention effect for tumor targeting. , 2006, Drug discovery today.
[7] Forrest M Kievit,et al. Surface engineering of iron oxide nanoparticles for targeted cancer therapy. , 2011, Accounts of chemical research.
[8] D. Owen,et al. Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[9] Ick Chan Kwon,et al. Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly(beta-amino ester) block copolymer micelles for cancer therapy. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[10] J. Macdiarmid,et al. Minicells: versatile vectors for targeted drug or si/shRNA cancer therapy. , 2011, Current opinion in biotechnology.
[11] Rakesh K. Jain,et al. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases , 2011, Nature Reviews Drug Discovery.
[12] Mauro Ferrari,et al. Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. , 2011, Accounts of chemical research.
[13] Yan Zhang,et al. Targeting therapy with mitosomal daunorubicin plus amlodipine has the potential to circumvent intrinsic resistant breast cancer. , 2011, Molecular pharmaceutics.
[14] H. Szeto. Mitochondria-targeted peptide antioxidants: Novel neuroprotective agents , 2006, The AAPS Journal.
[15] Xinguo Jiang,et al. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease. , 2011, International journal of pharmaceutics.
[16] U. Nielsen,et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.
[17] R. Jain,et al. Multistage nanoparticles for improved delivery into tumor tissue. , 2012, Methods in enzymology.
[18] W. Denny,et al. Targeting of nanoparticles in cancer: drug delivery and diagnostics , 2011, Anti-cancer drugs.
[19] Gaurav Sahay,et al. Endocytosis of nanomedicines. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[20] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[21] H. Kessler,et al. Ligands for mapping alphavbeta3-integrin expression in vivo. , 2009, Accounts of chemical research.
[22] L. Gerweck,et al. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. , 1996, Cancer research.
[23] Y. Oh,et al. Cationic drug-derived nanoparticles for multifunctional delivery of anticancer siRNA. , 2011, Biomaterials.
[24] H. Szeto,et al. Cell-permeable Peptide Antioxidants Targeted to Inner Mitochondrial Membrane inhibit Mitochondrial Swelling, Oxidative Cell Death, and Reperfusion Injury* , 2004, Journal of Biological Chemistry.
[25] F. Walker. Paclitaxel (TAXOL): side effects and patient education issues. , 1993, Seminars in oncology nursing.
[26] Z. Duan,et al. Modulation of Drug Resistance in Ovarian Adenocarcinoma by Enhancing Intracellular Ceramide Using Tamoxifen-Loaded Biodegradable Polymeric Nanoparticles , 2008, Clinical Cancer Research.
[27] Fabio Pastorino,et al. Targeted Drug Delivery and Penetration Into Solid Tumors , 2012, Medicinal research reviews.
[28] Mark B. Carter,et al. The Targeted Delivery of Multicomponent Cargos to Cancer Cells via Nanoporous Particle-Supported Lipid Bilayers , 2011, Nature materials.
[29] Mark E. Davis,et al. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles , 2009, Proceedings of the National Academy of Sciences.
[30] Jayanth Panyam,et al. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. , 2010, Biomaterials.
[31] Arjun G. Yodh,et al. Non-invasive assessment of tumor neovasculature: techniques and clinical applications , 2008, Cancer and Metastasis Reviews.
[32] N. Pante,et al. Nuclear pore complex is able to transport macromolecules with diameters of about 39 nm. , 2002, Molecular biology of the cell.
[33] Yang Wang,et al. Enhancement of the Efficacy of Chemotherapy for Lung Cancer by Simultaneous Suppression of Multidrug Resistance and Antiapoptotic Cellular Defense , 2004, Cancer Research.
[34] P. Zhang,et al. Amphiphilic polysaccharide-hydrophobicized graft polymeric micelles for drug delivery nanosystems. , 2011, Current medicinal chemistry.
[35] J. Xie,et al. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. , 2010, Biomaterials.
[36] Noritada Kaji,et al. Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid. , 2011, Biomaterials.
[37] S. Vallabhajosula,et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] Mark E. Davis,et al. Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.
[39] Qiang Zhang,et al. A novel stealth liposomal topotecan with amlodipine: apoptotic effect is associated with deletion of intracellular Ca2+ by amlodipine thus leading to an enhanced antitumor activity in leukemia. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[40] J. Au,et al. Paclitaxel tumor-priming enhances siRNA delivery and transfection in 3-dimensional tumor cultures. , 2011, Molecular pharmaceutics.
[41] Wei Liang,et al. Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. , 2007, Journal of the National Cancer Institute.
[42] Jeong Hoon Ko,et al. Development of MRI/NIRF 'activatable' multimodal imaging probe based on iron oxide nanoparticles. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[43] C Jeffrey Brinker,et al. Silica nanoparticle supported lipid bilayers for gene delivery. , 2009, Chemical communications.
[44] Warren C W Chan,et al. Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. , 2007, Nano letters.
[45] I. Khalil,et al. Octaarginine- and pH sensitive fusogenic peptide-modified nanoparticles for liver gene delivery. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[46] He Lian,et al. Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery. , 2011, International journal of pharmaceutics.
[47] Yu Zhang,et al. Lactoferrin-conjugated superparamagnetic iron oxide nanoparticles as a specific MRI contrast agent for detection of brain glioma in vivo. , 2011, Biomaterials.
[48] Yu-cheng Tseng,et al. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[49] J. Schellens,et al. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma , 2004, Cancer Chemotherapy and Pharmacology.
[50] D. Jaffray,et al. APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[51] Christine Allen,et al. In vivo fate of unimers and micelles of a poly(ethylene glycol)-block-poly(caprolactone) copolymer in mice following intravenous administration. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[52] A. Corti,et al. Synergistic Antitumor Activity of Cisplatin, Paclitaxel, and Gemcitabine with Tumor Vasculature-Targeted Tumor Necrosis Factor-α , 2006, Clinical Cancer Research.
[53] R Pasqualini,et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. , 2000, Cancer research.
[54] L. Huang,et al. Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. , 1992, Biochimica et biophysica acta.
[55] J. Israelachvili,et al. Formation of supported bilayers on silica substrates. , 2009, Langmuir : the ACS journal of surfaces and colloids.
[56] T. Ishida,et al. Synergistic antitumor activity of metronomic dosing of cyclophosphamide in combination with doxorubicin-containing PEGylated liposomes in a murine solid tumor model. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[57] Ajit S Narang,et al. Role of tumor vascular architecture in drug delivery. , 2011, Advanced drug delivery reviews.
[58] M. Bally,et al. In Vitro and in Vivo Characterization of Doxorubicin and Vincristine Coencapsulated within Liposomes through Use of Transition Metal Ion Complexation and pH Gradient Loading , 2004, Clinical Cancer Research.
[59] D. Welch,et al. Implications of tumor progression on clinical oncology , 1985, Clinical & Experimental Metastasis.
[60] Dae-Duk Kim,et al. Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[61] Xiaohua Ma,et al. Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.
[62] Tatiana Segura,et al. Utilizing cell-matrix interactions to modulate gene transfer to stem cells inside hyaluronic acid hydrogels. , 2011, Molecular pharmaceutics.
[63] Ji-Ho Park,et al. Cooperative nanomaterial system to sensitize, target, and treat tumors , 2009, Proceedings of the National Academy of Sciences.
[64] C. Klein,et al. The Metastasis Cascade , 2008, Science.
[65] H. Szeto. Cell-permeable, mitochondrial-targeted, peptide antioxidants , 2006, The AAPS Journal.
[66] Klaas Nicolay,et al. Dual-targeting of αvβ3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[67] Z. Werb,et al. New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.
[68] H. Maeda,et al. Tumoritropic and lymphotropic principles of macromolecular drugs. , 1989, Critical reviews in therapeutic drug carrier systems.
[69] K. Holmes,et al. SARS-associated coronavirus. , 2003, The New England journal of medicine.
[70] H Akita,et al. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid , 2007, Gene Therapy.
[71] Leaf Huang,et al. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[72] Peng Zhang,et al. Multifunctional nanoassemblies for vincristine sulfate delivery to overcome multidrug resistance by escaping P-glycoprotein mediated efflux. , 2011, Biomaterials.
[73] X. Wu,et al. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[74] Y. Pei,et al. PEGylated PAMAM Dendrimer-Doxorubicin Conjugates: In Vitro Evaluation and In Vivo Tumor Accumulation , 2010, Pharmaceutical Research.
[75] Warren C W Chan,et al. Nanoparticle-mediated cellular response is size-dependent. , 2008, Nature nanotechnology.
[76] R. Kurzrock,et al. Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer , 2007, Molecular Cancer Therapeutics.
[77] D. Jans,et al. Using nuclear targeting signals to enhance non‐viral gene transfer , 2002, Immunology and cell biology.
[78] Rongqin Huang,et al. Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma. , 2011, Biomaterials.
[79] Omid C Farokhzad,et al. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. , 2011, Accounts of chemical research.
[80] Michael S. Strano,et al. Size-dependent cellular uptake and expulsion of single-walled carbon nanotubes: single particle tracking and a generic uptake model for nanoparticles. , 2009, ACS nano.
[81] V. Labhasetwar,et al. Targeted Drug Delivery in Cancer Therapy , 2005, Technology in cancer research & treatment.
[82] Xianghui Xu,et al. Anti-tumor drug delivery of pH-sensitive poly(ethylene glycol)-poly(L-histidine-)-poly(L-lactide) nanoparticles. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[83] Angelo Corti,et al. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. , 2002, The Journal of clinical investigation.
[84] Yuexian Liu,et al. Anti-tumor activity of paclitaxel through dual-targeting carrier of cyclic RGD and transferrin conjugated hyperbranched copolymer nanoparticles. , 2012, Biomaterials.
[85] S. Rabbani,et al. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects , 2007, Anti-cancer drugs.
[86] Weili Lin,et al. Hybrid silica nanoparticles for multimodal imaging. , 2007, Angewandte Chemie.
[87] Rongqin Huang,et al. Choline‐Derivate‐Modified Nanoparticles for Brain‐Targeting Gene Delivery , 2011, Advanced materials.
[88] Darrell J Irvine,et al. Cytosolic delivery of membrane-impermeable molecules in dendritic cells using pH-responsive core-shell nanoparticles. , 2007, Nano letters.
[89] Chen Jiang,et al. Gene and doxorubicin co-delivery system for targeting therapy of glioma. , 2012, Biomaterials.
[90] Michael Hawkins,et al. Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol) , 2005, Clinical Cancer Research.
[91] Joseph M. DeSimone,et al. Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.
[92] B. Stillman,et al. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug , 2009, Nature Biotechnology.
[93] P. Imming,et al. Drugs, their targets and the nature and number of drug targets , 2006, Nature Reviews Drug Discovery.
[94] L. F. Nielsen,et al. Biodegradable nanocomposite microparticles as drug delivering injectable cell scaffolds. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[95] Kwangmeyung Kim,et al. Multi-core vesicle nanoparticles based on vesicle fusion for delivery of chemotherapic drugs. , 2011, Biomaterials.
[96] Kirsten Sandvig,et al. Endocytosis and intracellular transport of nanoparticles: Present knowledge and need for future studies , 2011 .
[97] Ze Lu,et al. Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming. , 2011, Nanomedicine.
[98] Mauro Ferrari,et al. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. , 2008, Nature nanotechnology.
[99] R. Huang,et al. Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts , 2010, Leukemia & lymphoma.
[100] M. Uesaka,et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. , 2011, Nature nanotechnology.
[101] R K Jain,et al. Noninvasive measurement of interstitial pH profiles in normal and neoplastic tissue using fluorescence ratio imaging microscopy. , 1994, Cancer research.
[102] Robert Langer,et al. Spatiotemporal controlled delivery of nanoparticles to injured vasculature , 2010, Proceedings of the National Academy of Sciences.
[103] Dai Fukumura,et al. Multistage nanoparticle delivery system for deep penetration into tumor tissue , 2011, Proceedings of the National Academy of Sciences.
[104] Peng Zhang,et al. Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[105] Kinam Park,et al. Targeted drug delivery to tumors: myths, reality and possibility. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[106] Cao Xie,et al. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[107] I. Aoki,et al. A tumor-environment-responsive nanocarrier that evolves its surface properties upon sensing matrix metalloproteinase-2 and initiates agglomeration to enhance T₂ relaxivity for magnetic resonance imaging. , 2011, Molecular pharmaceutics.
[108] Goutham Reddy,et al. Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[109] Ki-Bum Lee,et al. Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs. , 2011, Molecular pharmaceutics.
[110] C. Jeffrey Brinker,et al. Porous nanoparticle supported lipid bilayers (protocells) as delivery vehicles. , 2009, Journal of the American Chemical Society.
[111] Christine Allen,et al. The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. , 2010, Molecular pharmaceutics.
[112] Mark E. Davis,et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.
[113] S. Mitragotri,et al. Adaptive micro and nanoparticles: temporal control over carrier properties to facilitate drug delivery. , 2011, Advanced drug delivery reviews.
[114] A. Levinson. Cancer Therapy Reform , 2010, Science.
[115] Alexander V Kabanov,et al. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[116] Francesco Stellacci,et al. Effect of surface properties on nanoparticle-cell interactions. , 2010, Small.
[117] C. Shapiro,et al. Cardiac safety of liposomal anthracyclines. , 2004, Seminars in oncology.
[118] M. Dewhirst,et al. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. , 2006, Journal of the National Cancer Institute.
[119] Esther H Chang,et al. Does a targeting ligand influence nanoparticle tumor localization or uptake? , 2008, Trends in biotechnology.
[120] Xiaoling Fang,et al. Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. , 2011, Biomaterials.
[121] Z. Duan,et al. Biodistribution and Pharmacokinetic Analysis of Paclitaxel and Ceramide Administered in Multifunctional Polymer-Blend Nanoparticles in Drug Resistant Breast Cancer Model , 2008, Molecular pharmaceutics.